AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$RVMD

Kim Lorence H. sold $3.6M of RVMD (indirect holdings)

Kim Lorence H. sold 17,090 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $209.82 ($206.60–$212.27, $3.59M total) across 7 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kim Lorence H.
Published Sep 10, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RVMD
Bearish
medium confidence
Mentioned
$RVMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDBearishLow
01

Why it matters

The complete exit of a director could be interpreted as a lack of confidence, potentially prompting short sellers.

02

Market read

Insider sell may influence short-term price action in RVMD.

03

What to watch

The 10b5-1 plan pre-scheduled the sale, reducing informational value of the transaction.

Relevance 5/10Novelty 6/10Timing: Filed Sep 10, transaction occurred Sep 8

Background

SEC Form 4 filing discloses insider transactions; directors often use 10b5-1 plans for scheduled sales.

Company-level read

Ticker impact

$RVMDBearishMedium confidence
Context

Director Kim Lorence H. sold 17,090 shares for $3.6M via a 10b5-1 plan, reducing holdings to zero.

Expected impact

Potential short-term downside pressure as market digests the insider sell.

Evidence & confidence

Director exits completely, large sell amount relative to typical insider trades, suggests lack of confidence.

Market effects

Sector

May raise concerns for biotech sector if insider sells increase.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider may have needed liquidity; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    Revolution Medicines, Inc.

    Biotech firm developing oncology therapies.

  • Insider
    Kim Lorence H.

    Director of Revolution Medicines.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

SEP 28
$RVMDHigh

Brookline initiates Revolution Medicines stock with buy rating

Brookline Capital Markets initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a buy rating and a $318 price target. The stock is up 367% over the past year. Brookline estimates revenue growing from $151M in 2026 to $59.5B in 2033, with positive cash flow expected in 2027. The company recently launched Rasonque for pancreatic cancer, with FDA approval based on improved survival rates.

investing.com2 min
SEP 25
$RVMDMedAI 8/10

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.

aol.com3 min
SEP 24
$RVMDMed

Goldman Sparks Surge In Revolution Medicines Shares

Revolution Medicines (RVMD) shares rose after Goldman Sachs initiated coverage with a Buy rating and a $267 price target, citing its drug pipeline and deal activity. The company's cancer drug and pipeline offer growth potential, but risks include cash burn and regulatory uncertainties.

tipranks.com2 min